Mikaela Naylon Give Kids a Chance Act of 2025

This bill does two main things related to children's health. First, it makes it easier for researchers to test combinations of cancer drugs on children, including drugs that are already approved as standard treatments for kids' cancers or that are approved for adult cancers and target the same molecules involved in pediatric cancers. Second, it restarts a program, which expired in December 2024, that gives special rewards called priority review vouchers to companies that develop new treatments for rare diseases in children, extending it through September 30, 2030. The bill also requires the FDA and the Government Accountability Office to report on how well these changes are working to help develop new cancer and rare disease treatments for kids.

Your Vote